Janssen submits NDA for sirukumab in rheumatoid arthritis in Japan
Janssen Pharmaceutical submitted a New Drug Application to the Ministry of Health, Labour and Welfare, seeking approval of sirukumab for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
October 24, 2016